Assessment of Long Term Treatment With Testosterone Undecanoate in Males With Hypogonadism
Assessment of Long Term Treatment With Testosterone Undecanoate in Males With Hypogonadism
This study will evaluate the preparation of testosterone undecanoate under conditions which
 resemble real-life situations.
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been
 renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor
 of the trial.
Inclusion Criteria:

 -  Hypogonadal men, aged 18-75 years with low serum total testosterone (TT) levels and
 symptoms of androgen deficiency

 Exclusion Criteria:

 -  Tumors of the prostate or the male mammary gland including suspicion thereof. Past or
 present liver tumors or chronic hepatic disease with impairment of liver function,
 Severe acne.